

SCOUTING OF PRODUCTS FOR CENTRAL NERVOUS SYSTEM

GENESIS Biomed has been contacted by an International Pharma Company to carry out a screening of PRODUCTS focused on the Central Nervous System (CNS) therapeutic area.

The company is seeking PRODUCTS within Small Chemical Entities where Non marketed New Formulations for already existing CNS compounds and/or Off-label use of drugs in CNS could be considered. Our client seeks to identify and transfer such opportunities where priorities and/or resources have not allowed to complete the development and/or reach the market.

PROJECT SUMMARY

Introduction:

International pharma company is seeking new opportunities for already existing Small Chemical Entities in the CNS therapeutic area.

Project aim:

Detection of R&D opportunities, Small Chemical Entities exclusively, through a structured scouting process.

These opportunities will be generic medicines, mainly in the area of Central Nervous System, at any stage of development and within the European territory.

GENESIS Biomed:

GENESIS Biomed is a consultancy firm in the biomedical healthcare sector specialized in providing consulting services to spin-off, start-up companies, entrepreneurs, research centers and pharma companies.

OUR CLIENT:

The Company develops and manufactures Active Pharmaceutical Ingredients and Finished Dosage Forms. The company's products include antiacne agents, antidepressants, antifungals, antihistaminics, antiulceratives, antidiabetics, antihypertensives, antivirals, hypnotics, skeletal muscle relaxants. Company's aim is to increase the pharmaceutical business thanks to day-to-day collaboration with more than 500 active clients in over 60 countries offering them a broad portfolio of APIs and FDFs.

CALL INFORMATION

Molecules: Existing Small Chemical entities

Opportunity: New formulations (solid and liquid forms) and off-label use.

Therapeutic area: Central Nervous System.

Development stage: At least, rational or evidences at non-clinical level. Clinical outcomes will be welcome.

Intellectual property: Steady IP protection will be valued.

Procedure:

- Send non-confidential abstract including the description of the project and Institution/Company details to GENESIS Scouting Group. This abstract should explain rational or unmet need, potential therapeutic alternatives and the market opportunities beneath the proposed PRODUCT.
- On non-disclosure agreement approval between GENESIS and the originators, a full review of the evidences should be performed.
- Final projects will be evaluated and selected by our Client.

In case you are interested, please contact GENESIS Scouting Group (scouting@genesis-biomed.com)